Literature DB >> 3606898

Dipeptidyl-aminopeptidase II in human cerebrospinal fluid: changes in patients with Parkinson's disease.

M Hagihara, R Mihara, A Togari, T Nagatsu.   

Abstract

By using a sensitive and specific method, DAP II activity was found in CSF. DAP II activity in CSF of control patients without neurological diseases was 0.416 +/- 0.141 (mean +/- SD) nmole/min/ml and was higher than DAP IV activity in CSF, 0.221 +/- 0.062 (mean +/- SD) nmole/min/ml. In contrast, DAP II activity in serum was 1.16 +/- 0.16 (mean +/- SD) nmole/min/ml and was lower than serum DAP IV activity [41.85 +/- 3.36 (mean +/- SD) nmole/min/ml]. This relatively high activity of DAP II in CSF compared with the activity of DAP IV in CSF together with recent histochemical evidence on the localization of DAP II in some neurons (7) suggests that CSF DAP II may be derived from the brain and may be a marker of some peptidergic neurons. DAP II activity in CSF of patients with Parkinson's disease was significantly increased, whereas DAP IV activity in CSF did not change significantly.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3606898     DOI: 10.1016/0885-4505(87)90049-1

Source DB:  PubMed          Journal:  Biochem Med Metab Biol        ISSN: 0885-4505


  3 in total

Review 1.  Prolyl oligopeptidase and dipeptidyl peptidase II/dipeptidyl peptidase IV ratio in the cerebrospinal fluid in Parkinson's disease: historical overview and future prospects.

Authors:  Toshiharu Nagatsu
Journal:  J Neural Transm (Vienna)       Date:  2016-08-08       Impact factor: 3.575

Review 2.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505

3.  Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease.

Authors:  Simon Sjödin; Gunnar Brinkmalm; Annika Öhrfelt; Lucilla Parnetti; Silvia Paciotti; Oskar Hansson; John Hardy; Kaj Blennow; Henrik Zetterberg; Ann Brinkmalm
Journal:  Alzheimers Res Ther       Date:  2019-09-14       Impact factor: 6.982

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.